Ultrasonographic measurement of intra-abdominal fat thickness in HIV-infected patients treated or not with antiretroviral drugs and its correlation to lipid and glycemic profiles

Annals of Nutrition and Metabolism

Volumn 51, Issue 1, 2007, Pages 35-41

  Guimarães, Milena Maria Moreira ^a,b   De Oliveira Jr , Antônio Ribeiro ^a   Penido, Mariana Guimarães ^a   Queiroz, Leonardo Campos ^a   Goulart, Eugênio Marcos Andrade ^a   Greco, Dirceu Bartolomeu ^a   Machado, Lucas José De Campos ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b NONE   (Brazil)

Author keywords

Adipose tissue; Cardiovascular risk; HIV; Hypercholesterolemia; Hypertriglyceridemia; Insulin resistance; Lipodystrophy

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ADULT; AGED; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY MASS; BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IMPEDANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID BLOOD LEVEL; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; STUDENT T TEST; SUBCUTANEOUS FAT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST HIP RATIO;

ADULT; ANTHROPOMETRY; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INTRA-ABDOMINAL FAT; LIPIDS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 34247394184     PISSN: 02506807     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100819     Document Type: Article

References (50)

1. Miller KD, Jones E, Yanovski JA, Shankar R, Feuertein I, Falloon J: Visceral abdominal fat accumulation associated with use of indinavir. Lancet 1998;35:871-875.
2. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, et al: A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:51-58.
3. Visnegarwala F, Krause KL, Musher DM: Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997;127:947.
4. Viraben R, Aquilina C: Indinavir associated lipodystrophy. AIDS 1998;12:37-39.
5. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C: Definition of metabolic syndrome: Report of The National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition. Circulation 2004;109: 433-438.
6. Armellini F, Zamboni M, Robbi R, Todesco T, Rigo L, Bergamo-Andreis IA, et al: Total and intra abdominal fat measurements by ultrasound and computerized tomography. Int J Obes 1983;17:209-214.
7. Radominski RB, Hebroso DP, Cerri GG, Halpern A: O uso da ultra-sonografia na avaliação da distribuição de gordura abdominal. Arq Bras Endocrinol Metab 2000;44: 5-12.
8. Leite CC, Matsuda D, Wajchenberg BL, Cerri GG, Halpern A: Correlação da Medida de Espessura Intra-Abdominal Medida pela Ultra-Sonografia com os Fatores de Risco Cardiovascular. Arq Bras Endocrinol Metab 2000;44:49-56.
9. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turber RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 1985;28:412-419.
10. Lukaski HC: Methods for the assessment of human body composition: traditional and new. Am J Clin Nutr 1987;46:537-556.
11. Durnin GA, Womersley J: Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16-72 years. Br J Nutr 1974;32:77-97.
12. Ribeiro-Filho FF, Faria AN, Kohlmann O Jr, Ajzen S, Ribeiro AB, Zanella MT, et al: Ultrasonography for the evaluation of visceral fat and cardiovascular risks. Hypertension 2001;38:713-717.
13. Carr A, Samaras K, Chisholm DJ, Cooper DA: Pathogenesis of HIV-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998;351:1881-1883.
14. Zhang B, Macnaul K, Szalkowski P, Zhihua L, Berger J, Moller DE: Inhibition of adipocyte differentiation by HIV protease inhibitors. J Clin Endocrinol Metab 1999;84:4374-4377.
15. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, et al: Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002;359:1026-1031.
16. Ledru E, Christeff N, Patey O, Truchis P, Melchior JC, Gougeon ML: Alteration of tumor necrosis factor-a T-cell homeostasis following potent antiretroviral therapy; contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 2000;95:3191-3198.
17. Eagling VA, Black DJ, Barry MG: Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997;44:190-194.
18. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seck JR, et al: A transgenic model of visceral obesity and the metabolic syndrome. Science 2001;294: 2166-2170.
19. Murata H, Hruz PW, Mueckler M: The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000;275:20251-20254.
20. Walker UA, Bickel M, Lutke Volksbeck SI, Schofer H, Setzer B, Rickets, et al: Decrease of mitochondrial DNA content in adipose tissue of HIV-1-infected patients treated with NRTIs. Antivir Ther 2000;5:5.
21. Brinkman K, Smeitink JA, Romijn JA, Reiss P: Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-1115.
22. Medina DJ, Tsai CH, Hsiung GD, Cheng YC: Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three antihuman immunodeficiency virus dideoxynucleosides. Antimicrob Agents Chemother 1994;38:1824-1828.
23. Lewis LD, Strawbridge RR, McQuilkin SHAA: Potential intracellular target for 2'3′dideoxynosine (ddI) related pancreatic toxicity. Clin Pharmacol Ther 1998;63:180.
24. Kino T, Gragenov A, Kopp JB, Stauber RH, Pavlakis GN, Chrousos GP, et al: The HIV-1 virion-associated protein Vpr is a coactivator of the humanglucocorticoid receptor. J Exp Med 1999;189:51-62.
25. Kino T, Gragenov A, Slobodskaya O, Tsopanomichalou M, Chrousos PG, Pavlarkis GN: Human immunodeficiency virus type 1 accessory protein Vpr induces transcription of the HIV-1 and glucocorticoid-responsive promoters by binding directly to p300/CBP coactivators. J Virol 2002;76:9724-9734.
26. Capeau J, Caron M, Vigouroux C, Cervera P, Kim M, Maachi M, et al: Lipodystrophies related to antiretroviral treatment of HIV infection. Med Sci 2006;22:531-536.
27. Hogg RS, O'Shaughnessy MV, Gataric N, Yip B, Craib K, Schechter T, et al: Decline in deaths from aids due to new antiretrovirals (letter). Lancet 1997;349:1294.
28. Palella FJ Jr, Delaney KM, Moorrnan AC, Lovelless MO, Fuhrer J, Satten GA, et al: Declining of morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338: 853-860.
29. Ribeiro-Filho FF, Faria AN, Azjen S, Zanella MT, Ferreira SR: Methods of estimation of visceral fat: advantages of ultrasonography. Obes Res 2003;11:1488-1494.
30. Targher G, Tonoli M, Agostino G, Rigo L, Boschini K, Muggeo M, et al: Ultrasonographic intra-abdominal depth and its relation to haemostatic factors in healthy males. Int J Obes Relat Metab Disord 1996;20:882-885.
31. Leite CC, Wajchenberg BL, Radominski R, Matsuda D, Cerri GG, Halpern A: Intra-abdominal thickness by ultrasonography to predict risk factors for cardiovascular disease and its correlation with anthropometric measurements. Metabolism 2002;51:1034-1040.
32. Kondo I, Mizushige K, Hirao K, Nozaki S, Tsuji T, Masugata H, et al: Ultrasonographic assessment of coronary floor reserve and abdominal obesity. Ultrasound Med Biol 2001; 27:1199-1205.
33. Martínez E, Bianchi L, García-Viejo MA, Bru C, Gatell JM: Sonographic assessment of regional fat in HIV1-infected people. Lancet 2000;356:1412-1413.
34. Galli M, Cozzi-Lepri A, Ridolfo AL, Gervasoni C, Ravasio L, Corsico L, et al: Incidence of adipose tissue alterations in first line antiretroviral therapy: the LIPOCO study. Arch Intern Med 2002;162:2621-2628.
35. Carr A, Samaras S, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA: Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-2099.
36. Saint-Marc T, Partisani M, Pozot-Martin I, Rouviere O, Bruno F, Avellaneda R, et al: Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000;14:37-49.
37. Walli R, Herfort O, Michl GM, Demant T, Jäger H, Dieterle C, et al: Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998;12:F167-F173.
38. Hadigan C, Meigs B, Corcovan C, Rietschel P, Piecuch S, Bazgoz N, et al: Metabolic abnormalities and cardiovascular disease risk factor in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001;32:130-139.
39. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, et al: A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long term nucleoside analogue therapy. AIDS 1999;13: 1659-1667.
40. Addy CL, Gavrila A, Tsiodras S, Brodavicz K, Karchmer AW, Mantzoros CS: Hiypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in HIV-infected patients treated with HAART. J Clin Endocrinol Metab 2003;88: 627-636.
41. Gervasoni C, Ridolfo AL, Trifiro G, Santambrogio S, Norbiato G, Músico M, et al: Redistribution of body fat in HIV infected women undergoing combined antiretroviral therapy. AIDS 1999;13:465-471.
42. Thiébaut R, Daucout V, MerciéP, Ekoouèvi DK, Malvy D, Morlat P, et al: Lipodystrophy, metabolic disorders and human immunodeficiency virus infection: Aquitaine cohort, France, 1999. Clin Infect Dis 2000;31:1482-1487.
43. Nagy GS, Tsiodras S, Martin LD, Avihingsanon A, Gravila A, Willian CP, et al: Human immunodeficiency virus type 1-related lipoatrophy and lipohypertrophy are associated with serum concentrations of leptin. Clin Infect Dis 2003;36:795-802.
44. Berthold HK, Parhofer KG, Ritter MM, Addo M, Wasmuth JC, Schliefer K, et al: Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med 1999;246:567-575.
45. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, et al: Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23:3543.
46. Yanovski JA, Miller KD, Kino T, Friedman TC, Chrousos GP, Tsigos C, et al: Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab 1999; 84:1925-1931.
47. Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, Chave JP, et al: Premature atherosclerosis in HIV-infected individuals-focus on protease inhibitor therapy. AIDS 2001;15: 329-334.
48. Bacchetti P, Gripsshover B, Grunfeld C, Heymsfield S, McCreath H, Osmond D, et al: Fat distribution in men with HIV infection (from the Study of Fat Redistribution and Metabolic Change in HIV Infection). J Acquir Immune Defic Syndr 2005;40:121-131.
49. Hadigan C, Corcovan C, Stanley T, Piecuch S, Klibanski A, Grinspoon S: Fasting hyperinsulinemia in human immunodeficiency virus-infected men: relationship to body composition, gonadal function, and protease inhibitor use. J Clin Endocrinol Metab 2000; 85:35-41.
50. Kotler DP, Rosenbaum K, Wang J, Pierson RN: Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr 1999;20: 228-237.